Related Experiment Video
Updated: Jul 29, 2026

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 11, 2010
Increase in bone density and plasma osteocalcin during growth hormone therapy in growth hormone deficient children
F Greig1, E Greenfield, V Prasad
1Department of Pediatrics, Brookdale Hospital Medical Center, Brooklyn, New York, USA.
Insights
Growth hormone (GH) therapy improves bone density in children with GH deficiency. This study shows GH treatment significantly increases bone formation and mineralization, leading to sustained gains in bone density over two years.
Area of Science:
- Pediatric Endocrinology
- Bone Metabolism
- Growth Disorders
Background:
- Children with growth hormone (GH) deficiency exhibit reduced bone density beyond that explained by delayed skeletal maturation.
- Previous research indicates that GH administration enhances bone mineral retention and deposition.
Purpose of the Study:
- To evaluate the impact of two years of GH therapy on bone density and plasma osteocalcin levels in prepubertal children with GH deficiency.
Main Methods:
- Bone density of phalanges (cortical and trabecular bone) was measured using radiographic photodensitometry.
- Bone density was expressed as a standard deviation score (SDS) relative to sex, bone age, and chronological age.
- Plasma osteocalcin levels were measured before and during GH therapy.
Main Results:
- Relative osteopenia improved significantly during GH therapy, with bone density/chronological age (BD/CA) showing significant increases after 12 and 24 months.
- Bone density/bone age (BD/BA) also improved significantly after 24 months of GH therapy.
- Plasma osteocalcin levels, initially low, rose significantly within one week of GH therapy and remained elevated throughout the 24-month study period.
Conclusions:
- GH therapy in GH deficient children leads to an early and sustained increase in plasma osteocalcin.
- This is followed by a significant and prolonged enhancement of bone formation and mineralization, evidenced by improved bone density.
- GH therapy demonstrates a significant effect on bone health in addition to promoting linear growth in these children.
Unlabelled:
Bone density in growth hormone (GH) deficient children is decreased more than expected for delayed skeletal maturation. Previous studies suggest GH enhances mineral retention and deposition in bone. Seven GH deficient prepubertal children were studied during 2 years of GH therapy to assess the effect on bone density and plasma osteocalcin. Bone density (radiographic photodensitometry) of the phalanges (cortical and trabecular bone) was expressed as the standard deviation score (SDS) of the mean for sex, bone age and chronological age. Relative osteopenia, less pronounced for bone density/bone age (BD/BA) than bone density/chronological age (BD/CA), improved significantly during GH therapy. After 12 months there was increase over pretreatment levels, significant for BD/CA (-1.65 +/- 0.46 vs -1.15 +/- 0.64; mean +/- SD: p = 0.002), but less pronounced for BD/BA. After 24 months increase in both measurements continued, reaching significance also for BD/BA (Pre: -1.02 +/- 0.55 vs -0.41 +/- 0.29; p = 0.011). Plasma osteocalcin levels were low before GH therapy (11.6 +/- 9.9 ng/ml; n = 7; vs control 24.4 +/- 12.5 ng/ml; n = 21; p < 0.05), rose significantly after one week (31.2 +/- 10.5 ng/ml; p < 0.001), with continued upward trend to plateau between 2-6 months, with elevated levels persisting during 2 years of GH therapy.
Conclusion:
The early and sustained rise in plasma osteocalcin and subsequent increase in bone density with continued gain over 24 months of the study suggests that GH therapy in GH deficient children has a significant prolonged effect on bone formation and mineralization in addition to stimulating linear growth.
Related Concept Videos
Nature and Nurture
Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...

